Xvivo Perfusion AB
STO:XVIVO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
256.5
539
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xvivo Perfusion AB
Net Margin
Xvivo Perfusion AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | SE |
| Market Cap | 14.2B SEK |
| Net Margin |
27%
|
| Country | JP |
| Market Cap | 6.8T JPY |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.9B CHF |
| Net Margin |
12%
|
| Country | DK |
| Market Cap | 200.9B DKK |
| Net Margin |
19%
|
| Country | US |
| Market Cap | 16.9B USD |
| Net Margin |
11%
|
| Country | KR |
| Market Cap | 9.9T KRW |
| Net Margin |
-358%
|
| Country | CA |
| Market Cap | 6.9B USD |
| Net Margin |
-8%
|
| Country | CN |
| Market Cap | 48.6B CNY |
| Net Margin |
42%
|
| Country | US |
| Market Cap | 6.3B USD |
| Net Margin |
29%
|
| Country | US |
| Market Cap | 6.1B USD |
| Net Margin |
9%
|
| Country | UK |
| Market Cap | 4.8B GBP |
| Net Margin |
7%
|
Xvivo Perfusion AB
Glance View
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Xvivo Perfusion AB's most recent financial statements, the company has Net Margin of 27.2%.
You don't have any saved screeners yet
